62 Result(s)

Article

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis

Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B. Grade FL3A frequently coexists with FL1-2 (FL1-2-3A). Based on clinical trials, FL1-2 is treated with rituxim...

M. Pouyiourou, A. Meyer, A. Stroux, A. Viardot, P. La Rosée… in Annals of Hematology (2020)

Article

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

Treatment of patients (pts) with acute myelogenous leukaemia (AML) above 60 years remains a challenge. We report long-term follow-up of the AML97 study, where pts were registered at diagnosis and received trea...

C. Kahl, R. Krahl, C. Becker, H. K. Al-Ali… in Journal of Cancer Research and Clinical On… (2016)

Article

Erfolgreiche Zertifizierung eines nichtuniversitären Onkologischen Zentrums am HELIOS Klinikum Erfurt

Ein wesentlicher Zentrumsgedanke besteht darin, dass ungeachtet des Zugangs eines Tumorpatienten jede einzelne Klinik dieses Zentrums dessen Behandlungskonzept durch ein Tumorboard festlegen lässt. Nur durch e...

Dr. H. Göbel, A. Stier, D. Barwitzki, M. Herold in Der Onkologe (2012)

Chapter

Diagnostik

Die Diagnose einer rheumatischen Erkrankung stützt sich vordergründig auf die Anamnese und die klinischen Symptome, objektiv erhebbare Befunde wie Röntgen und Labor sind nur Ergänzungen zur Bestätigung einer V...

M. Herold, W. Siegmeth, M. Sabeti-Aschraf, G. Steiner… in Praktische Rheumatologie (2012)

Chapter

Andere Erkrankungen

Entzündliche, selten vorkommende Systemerkrankung des Knorpels mit fortschreitendem Knorpelabbau und Zerstörung anderer Bindegewebsstrukturen, als primäres Leiden eigene Entität; sekundär bei verschiedenen ent...

M. Herold, H. Bröll, M. Aringer, W. Graninger, Ch. Granitz… in Praktische Rheumatologie (2012)

Chapter

The Use of Metabolomics in Cancer Research

The use of metabolite profiling techniques (metabonomics or metabolomics) in toxicology is a relatively new branch of this science. Due to their unique biochemical properties, cancer cells should, in principle...

B. van Ravenzwaay, G. C. Cunha, E. Fabian… in An Omics Perspective on Cancer Research (2010)

Article

Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic

The efficacy of biological agents has been shown in several randomized clinical trials. However, little is known regarding the performance of these drugs in daily rheumatological care. Totally, 173 patients tr...

C. Duftner, C. Dejaco, H. Larcher, M. Schirmer, M. Herold in Rheumatology International (2008)

Chapter and Conference Paper

Successful Treatment of a Patient with High Titer Acquired Factor VIII Inhibitor (114 BU) with Rituximab

Acquired hemophilia is a rare severe bleeding disorder caused by antibodies against coagulation factors. Factor VIII is the commonest factor affected.

Frau Dr. Ch. Schubert, M. Herold in 37^th Hemophilia Symposium (2008)

Article

Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes

J Loeffler-Ragg, M Steurer, H Ulmer, S Skvortsov, B Kircher, M Herold… in Leukemia (2006)

Article

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Purpose: This randomized phase III study compared bendamustine and prednisone (BP) to standard melphalan and prednisone (MP) treatment in previously untreated patients with multiple Myeloma (MM). Patients and Met...

W. Pönisch, P. S. Mitrou, K. Merkle… in Journal of Cancer Research and Clinical On… (2006)

Article

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Purpose: The purpose of this study was to compare the efficacy and toxicity of bendamustine, vincristine + prednisone (BOP) with a standard regimen of cyclophosphamide, vincristine + pred...

M. Herold, A. Schulze, D. Niederwieser… in Journal of Cancer Research and Clinical On… (2006)

Article

Indirect evidence for neutralinos as dark matter

From the relic density measurement by WMAP the WIMP annihilation cross section can be determined in a model independent way. If the WIMPS are postulated to be the neutralinos of Supersymmetry, then only a limi...

W. de Boer, M. Herold, C. Sander, V. Zhukov in The European Physical Journal C - Particle… (2004)

Article

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

M. Herold, G. Dölken, F. Fiedler, A. Franke, M. Freund, W. Helbig… in Annals of Hematology (2003)

Article

Chronische lymphatische Leukämie Aktuelle Therapiekonzepte

Die chronische lymphatische Leukämie (CLL) ist die häufigste Leukämie der westlichen Welt. In den letzten 10 Jahren haben sich die Konzepte zur Therapie der CLL erheblich geändert. Neue Therapieverfahren wie P...

M. Hallek, M. Bergmann, G. Brittinger, H. Döhner, P. Dreger, M. Herold… in Der Internist (2002)

Article

Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine

The costs of chemotherapy toxicity were analyzed in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL). A total of 91 specialists regularly treating NHL were interviewed by telephone to identify the...

M. Herold, K. Hieke in The European Journal of Health Economics (2002)